NASDAQ: GRCEGrace Therapeutics Inc Stock
$2.80-0.22 (-7.28%)
Updated May 8, 2025
GRCE Price
$2.80
Fair Value Price
$2.24
Market Cap
$28.39M
52 Week Low
$1.75
52 Week High
$4.97
P/E
-2.41x
P/B
0.54x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$13.37M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.17
Operating Cash Flow
-$14M
Beta
0.86
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
GRCE Overview
Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal betamethasone spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. The company was formerly known as Acasti Pharma Inc. and changed its name to Grace Therapeutics, Inc. in October 2024. The company was incorporated in 2002 and is headquartered in Princeton, New Jersey.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine GRCE's potential to beat the market
- GRCE doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
GRCE
RankedUnranked of 457
RankedUnranked of 457
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $2.89 | A | |
| $42.51 | A | |
| $8.11 | A |
Be the first to know about important GRCE news, forecast changes, insider trades & much more!
GRCE News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how GRCE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
GRCE ($2.80) is overvalued by 25.12% relative to our estimate of its Fair Value price of $2.24 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
GRCE ($2.80) is not significantly undervalued (25.12%) relative to our estimate of its Fair Value price of $2.24 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
GRCE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more GRCE due diligence checks available for Premium users.
Valuation
GRCE fair value
Fair Value of GRCE stock based on Discounted Cash Flow (DCF)
Price
$2.80
Fair Value
$2.24
Overvalued by
25.12%
GRCE ($2.80) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GRCE ($2.80) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
GRCE is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
GRCE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.41x
Industry
-168.76x
Market
24.22x
GRCE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.54x
Industry
4.15x
GRCE is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
GRCE's financial health
Profit margin
Revenue
$0.0
Net Income
-$4.2M
Profit Margin
0%
GRCE's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$61.2M
Liabilities
$9.1M
Debt to equity
0.17
GRCE's short-term assets ($11.94M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GRCE's short-term assets ($11.94M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GRCE's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
GRCE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$4.1M
Investing
$15.0k
Financing
$0.0
GRCE's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
GRCE vs Biotech Stocks
Grace Therapeutics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.